US$ 25.78
glp-1 antagonist drugs Evolution of GLP‐1 Receptor Agonists for Diabetes Treatment The anti-inflammatory and immunological properties
Description
Led by Dr

Retatrutide targets GLP-1, GIP & glucagon receptors

GLP-1R agonist 2 has the potential for research in metabolic diseases such as type 2 diabetes and obesity

NP-supervised, in-person care

Professional tirzepatide therapy includes complete injection kit with syringes and free telehealth support
Eli Lillys first nine months of 2025 underscored the scale of the GLP-1 surge: Mounjaro and Zepbound generated $39.5 billion in revenue and surpasses Mercks Keytruda as the worlds best-selling medicine[5]
